STYLE SHEET
GLOBAL CSS
COLORS
ANIMATIONS
MEDIA QUERY
SPACING SYSTEM

Shortages and concerns arise as weight-loss injections gain popularity

Weight-loss injections like Ozempic and Wegovy have gained significant attention, even from celebrities like Elon Musk and Amy Schumer. European startups are entering the market to provide treatment plans using semaglutide, the active ingredient in these medications. 

However, the surge in demand for semaglutide is causing concerns, particularly for diabetic patients, as the drug becomes less accessible. Some startups are offering online prescriptions for the drug, potentially making it too easily available. This article explores the challenges and controversies surrounding the availability of semaglutide for weight loss.

Yazen offers a comprehensive approach to weight loss that focuses on weight stability over time. Through our service and platform, our customers have access to medical professionals, including doctors, dietitians, personal trainers, and psychologists. 

We combine this expert support with modern medications like Ozempic, known for its effectiveness in aiding weight loss. Yazen's approach involves ongoing monitoring and support, ensuring that individuals not only lose weight but also maintain their new weight in the long term. With a team of specialists and continuous follow-up, Yazen helps users make necessary lifestyle changes for sustained, stable weight loss over time.

Stay informed about the evolving landscape of weight-loss treatments and seize the opportunities it presents.

Read the full article on Sifted

Start your weight loss journey with Yazen today

Everything you need to do is to create an account and answer some questions about your health

Get Started
Get Started
Get Started

More news

Press release
Yazen Health closes €19.5M series A to drive global growth

Yazen Health has successfully closed an oversubscribed €19.5 million series A funding round to fuel its international expansion. This investment enables Yazen to enhance its pioneering obesity treatment model, combining modern weight loss medication with comprehensive lifestyle support.

News
Sifted UK: Yazen raises €19.5m to expand obesity treatment in the EU

Yazen has secured €19.5 million in Series A funding to expand its GLP-1-based obesity treatment across Europe. The company combines medication with lifestyle support for sustainable weight loss results.

News
Lasker~DeBakey Award 2024 for groundbreaking GLP-1 obesity research

Lasker~DeBakey Award 2024 for groundbreaking GLP-1 obesity research